Armata Pharmaceuticals (ARMP) Q4 2024 earnings summary

Executive summary

• Achieved significant clinical milestones with positive topline results from Phase 2 Tailwind study for inhaled AP-PA02 in NCFB patients and completed enrollment for Phase 1b/2a diSArm study for IV AP-SA02 in S. aureus bacteremia.

• Advanced bacteriophage science through key presentations and a structural biology publication.

• Entered into a $10 million secured credit agreement in March 2025 to support ongoing operations.

Financial highlights

• Grant revenue for Q4 2024 was $1.2 million, down from $1.5 million in Q4 2023.

• Research and development expenses rose to $8.5 million in Q4 2024 from $7.9 million in Q4 2023.

• General and administrative expenses were $3.3 million in Q4 2024, up slightly from $3.2 million in Q4 2023.

• Net income for Q4 2024 was $2.6 million ($0.07 per basic share), compared to a net loss of $19.8 million ($-0.55 per share) in Q4 2023, driven by non-cash gains from convertible loan fair value changes and debt extinguishment.

• Cash and equivalents as of December 31, 2024, totaled $14.8 million, down from $19.2 million at year-end 2023.

Outlook and guidance

• Topline data from the diSArm study expected in the first half of 2025, with plans to discuss pivotal trial design with the FDA.

• Anticipates achieving value-creating milestones in 2025, focusing on advancing phage therapy as an alternative to antibiotics.